Menu Search
Equities

Supernus Pharmaceuticals Inc

S49:DUS

Supernus Pharmaceuticals Inc

Actions
  • Price (EUR)35.20
  • Today's Change1.20 / 3.53%
  • Shares traded180.00
  • 1 Year change+43.09%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 07:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Supernus Pharmaceuticals Inc's revenues fell -8.95% from 667.24m to 607.52m. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from 60.71m to 1.32m, a -97.83% decrease.
Gross margin89.04%
Net profit margin9.16%
Operating margin9.09%
Return on assets4.54%
Return on equity6.22%
Return on investment5.83%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Supernus Pharmaceuticals Inc fell by 18.07m. However, Cash Flow from Investing totalled 268.73m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company generated 111.09m in cash from operations while cash used for financing totalled 397.88m.
Cash flow per share2.57
Price/Cash flow per share14.61
Book value per share18.24
Tangible book value per share6.34
More ▼

Balance sheet in USDView more

Supernus Pharmaceuticals Inc uses little or no debt in its capital structure.
Current ratio2.20
Quick ratio1.98
Total debt/total equity0.00
Total debt/total capital0.00
More ▼

Growth rates in USD

SmartText is unavailable
EPS growth(5 years)-59.02
EPS (TTM) vs
TTM 1 year ago		147.69
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.